Author: MASTERDDI

Mediseen eHealth will be attending HIMSS19, Feb 11-15, 2019, Orlando. You will find us in Booth #911, together with Sheba ( ARC) in the CDI Negev Pavilion. We would be happy to meet you there!  If you wish to arrange a meeting with one of our executive management, please contact the following email: infous@mediseen-ehealth.com We hope to see you there!  ...

Read More

Mediseen eHealth presented at the largest Pharmacy  Association conference in Israel, in front of 550 pharmacists from all the industry. Our founder & CEO, Dr. Roni Shiloh, presented the next generation of clinical decision support system for managing drug related problems-  Seegnal ...

Read More

Mediseen ehealth hosted a 2 day conference with renowned experts in the field of drug interactions: Prof. John Horn, University of Washington, Prof. Dan Malone, University of Arizona, Prof. David Bates, Brigham & Women’s Hospital . As part of these 2 days, Mediseen ehealth hosted a premium, intimate meeting with 100 clinicians who came to listen to the future of drug interactions’ management and the role of Seegnal....

Read More

  ABSTRACT Objectives: The risk of clinically significant drug-related problems is a major concern, particularly among elderly, polypharmacy-treated patients. Previous efforts to develop computerized alert systems have shown limited effectiveness. The purpose of this study was to evaluate the efficacy of a novel technology, the Drug-Drug Interaction Plus (DDI+) decision support system, used in a real-world ambulatory health maintenance organization (HMO) setting and developed to overcome the limitations of currently available programs. Study Design: Controlled trial. Methods: We conducted a controlled trial of the DDI+ system in Leumit Health Services (LHS), an HMO in Israel that provides coverage to approximately 700,000 members with approximately 2000 physicians nationally. All LHS physicians were geographically allocated by region to a study or control arm. Physician access rates, alert resolution rates, and resource utilization of their patients were evaluated and compared between the intervention and control arms. Results: There were 5.6% (P = .001) fewer mean episodes of hospitalization, 1.5% (P = .01) fewer mean drugs dispensed, and 2.1% (P = .055) fewer mean episodes of imaging in the intervention population versus controls. Drug-related problems that were re-encountered were often rectified without re-accessing the system. Conclusions: Comparing the acceptance by physicians of the DDI+ system to reports of acceptance of similar systems, DDI+ was observed to be better accepted. This will possibly initiate improvements in resource utilization patterns. We surmise that improved physician willingness to access the system can be attributed to the novel graphic presentation, specificity, and integration of DDI+ into the work flow of routine clinical practice. Am J Pharm Benefits. 2017;9(2):41-46 Courtesy of The American Journal of Pharmacy Benefits   Click here for the full article...

Read More